IL18BP and idiopathic pulmonary fibrosis: However, high levels of IL-18BP, a natural antagonist of IL-18, are associated with reduced overall survival in IPF patients (Nakanishi et al., 2021), suggesting that the activity of IL-18 may be required for improved survival or alternatively that high levels of IL-18 are accompanied by more IL-18BP, which leads to poorer outcomes.